Key result
Myosin inhibitors cut septal reduction therapy eligibility to ~ with placebo in HOCM.
Why the study?
Emerging pharmacologic options, including myosin inhibitors, are changing the landscape of traditional medical and septal reduction therapies for hypertrophic obstructive cardiomyopathy, prompting a comprehensive overview of current treatment options.
Answers are grounded in this paper and cite their sources.
This review summarizes the management of hypertrophic obstructive cardiomyopathy, highlighting how targeted cardiac myosin inhibitors (mavacamten and aficamten) complement traditional pharmacotherapy and invasive septal reduction therapies by directly modulating sarcomeric hypercontractility.
Hypertrophic obstructive cardiomyopathy (HOCM) is characterised by left ventricular outflow tract obstruction (LVOTO) caused by septal hypertrophy and its interaction with the mitral valve and systolic anterior motion. Symptoms include dyspnoea, angina, palpitations, syncope, fatigue and sudden cardiac death. This review provides a comprehensive overview and breakdown of current available treatment options, including traditional medical therapies and surgical septal reduction therapies in the era of new emerging pharmacologic options, including myosin inhibitors. Traditional pharmacotherapy includes non-vasodilating beta blockers, calcium-channel blockers and disopyramide. For persistent symptoms, surgical myectomy and alcohol septal ablation remain important septal reduction therapies, with treatment choice depending on anatomy, procedural risk and site-specific expertise. Myosin inhibitors, including mavacamten and aficamten, offer a targeted approach to addressing the hypercontractility characteristic of hypertrophic obstructive cardiomyopathy, by directly modulating sarcomeric function. These agents may move earlier in the treatment pathway for selected patients with HOCM, although longer-term data, access, monitoring burden and cost-effectiveness remain important considerations.
No takes yet. Share an insight, caveat, or question.
Nwuba et al. (2026) conducted a review in Hypertrophic obstructive cardiomyopathy (HOCM). Cardiac myosin inhibitors (mavacamten and aficamten), traditional pharmacotherapy, and septal reduction therapies vs. Placebo, standard medical therapy (beta-blockers, calcium-channel blockers, disopyramide), surgical myectomy, or alcohol septal ablation was evaluated. Myosin inhibitors (mavacamten and aficamten) effectively reduce LVOT gradients and symptoms in HOCM, reducing septal reduction therapy eligibility to with placebo in VALOR-HCM.
Synapse has enriched 10 related papers. Consider them for comparative context: